Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation

Area of Science:

• Cardiovascular Medicine
• Immunology
• Genetics

Background:

• High lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Lp(a) is implicated in cardiovascular disease (CVD) through pro-inflammatory effects, particularly its association with oxidized phospholipids (oxPL).
• Elevated Lp(a) is observed in inflammatory conditions like rheumatoid arthritis (RA), systemic lupus erythematosus, AIDS, and chronic renal failure.

Purpose of the Study:

• To review the role of Lp(a) in inflammation and its contribution to cardiovascular disease.
• To explore the mechanisms linking Lp(a) to inflammation and CVD.
• To contextualize emerging therapies targeting Lp(a) reduction.

Main Methods:

• Review of existing genome-wide association, epidemiological, and clinical studies.
• Analysis of the relationship between Lp(a), inflammation, and cardiovascular outcomes.
• Examination of the potential role of interleukin-6 (IL-6) in Lp(a) regulation.

Main Results:

• High Lp(a) is a significant risk factor for ASCVD, with mechanisms involving pro-inflammatory pathways.
• Association between Lp(a) and inflammatory conditions suggests a complex interplay.
• Interleukin-6 receptor (IL-6R) blockade in RA reversed high Lp(a), indicating IL-6's potential regulatory role.

Conclusions:

• Lp(a) plays a critical role in inflammation and CVD pathogenesis.
• Further understanding of Lp(a) mechanisms is essential for developing effective treatments.
• Ongoing clinical trials targeting apo(a) reduction will clarify the impact of lowering Lp(a) on cardiovascular outcomes.